Merck & Co’s new combo asthma drug expected to garner peak year sales of over $250 million


Following its expected launch this year for the treatment of asthma, US drug major Merck & Co's formoterol/mometasone…

AstraZenecaBudesonideBudesonide and Formoterol Fumarate DihydrateEntocort ECGlaxoSmithKlineGlobalGSKMarkets & MarketingMerck KGaAPharmaceuticalPulmicort TurbuhalerRespiratory and PulmonaryRhinocort AquaSymbicort

Spiriva closes the gap in patient share with Advair for COPD treatment in USA


Since a 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva…

AstraZenecaBoehringer IngelheimBudesonideBudesonide and Formoterol Fumarate DihydrateEntocort ECGlaxoSmithKlineGSKMarkets & MarketingNorth AmericaPfizerPharmaceuticalPulmicort TurbuhalerRespiratory and PulmonaryRhinocort AquaSpirivaSymbicorttiotropium

Back to top